DekaBank Deutsche Girozentrale Raises Stock Position in Pfizer Inc. $PFE

Key Points

• DekaBank Deutsche Girozentrale increased its stake in Pfizer by 0.3%, owning 7,398,373 shares worth approximately $179.7 million as of the latest SEC filing.
• Pfizer's recent earnings report showed an EPS of $0.78, exceeding analysts' expectations, with revenues of $14.65 billion for the quarter.
• The company declared a quarterly dividend of $0.43 per share, with an annualized yield of 7.0%, scheduled for payment on December 1st.

DekaBank Deutsche Girozentrale boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 0.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,398,373 shares of the biopharmaceutical company's stock after acquiring an additional 18,753 shares during the period. DekaBank Deutsche Girozentrale owned 0.13% of Pfizer worth $179,691,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. GKV Capital Management Co. Inc. purchased a new position in Pfizer during the first quarter valued at approximately $27,000. Bayforest Capital Ltd bought a new stake in Pfizer during the first quarter valued at approximately $28,000. North Capital Inc. bought a new stake in Pfizer during the first quarter valued at approximately $28,000. Harbor Asset Planning Inc. bought a new stake in Pfizer during the second quarter valued at approximately $29,000. Finally, WPG Advisers LLC bought a new stake in Pfizer during the first quarter valued at approximately $35,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.68 on Tuesday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.22. The stock has a market capitalization of $140.33 billion, a price-to-earnings ratio of 13.13, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. The company has a fifty day moving average of $24.89 and a 200-day moving average of $24.12. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the prior year, the company earned $0.60 EPS. The firm's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer's dividend payout ratio is currently 91.49%.

Analyst Ratings Changes

PFE has been the subject of several research analyst reports. Bank of America lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday, October 8th. Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Finally, Morgan Stanley cut their price objective on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a research note on Friday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.